^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    STK11 mutation + TMB-H

    i
    Other names: Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19, TMB | Tumor Mutational Burden
    Entrez ID:
    6794
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1year
    Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort. (PubMed, Tumori)
    Co-mutation STK11/KRAS is common among patients with non-small cell lung cancer and is not an independent predictive marker for the efficacy of immune checkpoint inhibitors. Further studies are required to clarify the role of STK11 mutations in immune checkpoint inhibitor treatment response.
    Real-world evidence • Journal • Tumor mutational burden • IO biomarker • Pan tumor • Real-world
    |
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • TMB-H • STK11 mutation • STK11 mutation + TMB-H
    |
    MSK-IMPACT